volume 22 issue 3 pages 147-157

TCF1 in T cell immunity: a broadened frontier

Xudong Zhao 1
Qiang Shan 2
2
 
Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, USA
3
 
New Jersey Veterans Affairs Health Care System, East Orange, USA
Publication typeJournal Article
Publication date2021-06-14
scimago Q1
wos Q1
SJR17.458
CiteScore84.7
Impact factor60.9
ISSN14741733, 14741741
Energy Engineering and Power Technology
Fuel Technology
Abstract
TCF1 and its homologue LEF1 are historically known as effector transcription factors downstream of the WNT signalling pathway and are essential for early T cell development. Recent advances bring TCF1 into the spotlight for its versatile, context-dependent functions in regulating mature T cell responses. In the cytotoxic T cell lineages, TCF1 is required for the self-renewal of stem-like CD8+ T cells generated in response to viral or tumour antigens, and for preserving heightened responses to checkpoint blockade immunotherapy. In the helper T cell lineages, TCF1 is indispensable for the differentiation of T follicular helper and T follicular regulatory cells, and crucially regulates immunosuppressive functions of regulatory T cells. Mechanistic investigations have also identified TCF1 as the first transcription factor that directly modifies histone acetylation, with the capacity to bridge transcriptional and epigenetic regulation. TCF1 also has the potential to become an important clinical biomarker for assessing the prognosis of tumour immunotherapy and the success of viral control in treating HIV and hepatitis C virus infection. Here, we summarize the key findings on TCF1 across the fields of T cell immunity and reflect on the possibility of exploring TCF1 and its downstream transcriptional programmes as therapeutic targets for improving antiviral and antitumour immunity. The transcription factor TCF1 is essential for early T cell development, and recent advances have uncovered context-dependent functions in mature T cells. This review summarizes key findings on TCF1 across the field of T cell immunity and explores their translational potential.
Found 
Found 

Top-30

Journals

2
4
6
8
10
12
14
Frontiers in Immunology
14 publications, 7%
Nature Immunology
13 publications, 6.5%
Journal of Experimental Medicine
7 publications, 3.5%
Journal of Immunology
6 publications, 3%
Nature Communications
5 publications, 2.5%
Journal for ImmunoTherapy of Cancer
5 publications, 2.5%
Proceedings of the National Academy of Sciences of the United States of America
5 publications, 2.5%
Cell
4 publications, 2%
Scientific Reports
4 publications, 2%
Immunity
3 publications, 1.5%
British Journal of Cancer
3 publications, 1.5%
Signal Transduction and Targeted Therapy
3 publications, 1.5%
Cell Reports Medicine
3 publications, 1.5%
Aging Cell
3 publications, 1.5%
Science immunology
3 publications, 1.5%
Frontiers in Microbiology
2 publications, 1%
Nature
2 publications, 1%
Communications Biology
2 publications, 1%
Trends in Immunology
2 publications, 1%
Journal of Leukocyte Biology
2 publications, 1%
bioRxiv
2 publications, 1%
Cell Reports
2 publications, 1%
Cancer Immunology, Immunotherapy
2 publications, 1%
Immunological Reviews
2 publications, 1%
Cancer Cell
2 publications, 1%
Cellular and Molecular Immunology
2 publications, 1%
Journal of Infectious Diseases
2 publications, 1%
Nature Reviews Bioengineering
1 publication, 0.5%
Life
1 publication, 0.5%
2
4
6
8
10
12
14

Publishers

10
20
30
40
50
60
Springer Nature
59 publications, 29.5%
Elsevier
31 publications, 15.5%
Cold Spring Harbor Laboratory
22 publications, 11%
Frontiers Media S.A.
19 publications, 9.5%
Wiley
12 publications, 6%
Rockefeller University Press
8 publications, 4%
BMJ
6 publications, 3%
The American Association of Immunologists
5 publications, 2.5%
MDPI
5 publications, 2.5%
Proceedings of the National Academy of Sciences (PNAS)
5 publications, 2.5%
Taylor & Francis
5 publications, 2.5%
American Association for Cancer Research (AACR)
4 publications, 2%
Oxford University Press
4 publications, 2%
American Association for the Advancement of Science (AAAS)
4 publications, 2%
American Chemical Society (ACS)
3 publications, 1.5%
American Society for Clinical Investigation
2 publications, 1%
European Molecular Biology Organization
1 publication, 0.5%
American Society for Microbiology
1 publication, 0.5%
OAE Publishing Inc.
1 publication, 0.5%
Begell House
1 publication, 0.5%
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.5%
10
20
30
40
50
60
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
201
Share
Cite this
GOST |
Cite this
GOST Copy
Zhao X. et al. TCF1 in T cell immunity: a broadened frontier // Nature Reviews Immunology. 2021. Vol. 22. No. 3. pp. 147-157.
GOST all authors (up to 50) Copy
Zhao X., Shan Q., Xue H. TCF1 in T cell immunity: a broadened frontier // Nature Reviews Immunology. 2021. Vol. 22. No. 3. pp. 147-157.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41577-021-00563-6
UR - https://doi.org/10.1038/s41577-021-00563-6
TI - TCF1 in T cell immunity: a broadened frontier
T2 - Nature Reviews Immunology
AU - Zhao, Xudong
AU - Shan, Qiang
AU - Xue, Hai-Ping
PY - 2021
DA - 2021/06/14
PB - Springer Nature
SP - 147-157
IS - 3
VL - 22
PMID - 34127847
SN - 1474-1733
SN - 1474-1741
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Zhao,
author = {Xudong Zhao and Qiang Shan and Hai-Ping Xue},
title = {TCF1 in T cell immunity: a broadened frontier},
journal = {Nature Reviews Immunology},
year = {2021},
volume = {22},
publisher = {Springer Nature},
month = {jun},
url = {https://doi.org/10.1038/s41577-021-00563-6},
number = {3},
pages = {147--157},
doi = {10.1038/s41577-021-00563-6}
}
MLA
Cite this
MLA Copy
Zhao, Xudong, et al. “TCF1 in T cell immunity: a broadened frontier.” Nature Reviews Immunology, vol. 22, no. 3, Jun. 2021, pp. 147-157. https://doi.org/10.1038/s41577-021-00563-6.